Arcturus Therapeutics (NASDAQ:ARCT) Receives Overweight Rating from Cantor Fitzgerald

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday,Benzinga reports.

Several other research firms also recently weighed in on ARCT. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday, February 14th. Finally, BTIG Research began coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Arcturus Therapeutics has an average rating of “Buy” and a consensus price target of $62.00.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded down $1.20 during mid-day trading on Friday, hitting $14.77. The company’s stock had a trading volume of 189,364 shares, compared to its average volume of 407,195. The stock’s fifty day simple moving average is $17.00 and its two-hundred day simple moving average is $18.64. The firm has a market capitalization of $399.99 million, a P/E ratio of -6.65 and a beta of 2.62. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. On average, equities analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ARCT. Wellington Management Group LLP increased its holdings in shares of Arcturus Therapeutics by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock worth $1,647,000 after acquiring an additional 742 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Arcturus Therapeutics by 10.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 846 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 883 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Arcturus Therapeutics by 7.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock valued at $323,000 after acquiring an additional 1,279 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.